Johnson & Johnson will recruit participants for its vaccine trial in the U.S., Argentina, Brazil, Chile, Colombia, Mexico, Peru and South Africa. Cheryl Gerber/Johnson & Johnson, via Associated Press
Trial Vaccines continue
A one-shot vaccine enters final testing in the U.S.
Johnson & Johnson has begun the final stage of clinical trials for a coronavirus vaccine that could have a big advantage over its competitors: It would require just one shot instead of two.
The trials, which began on Monday, will be the largest in the U.S., with plans to enrol 60,000 participants. “It would be fabulous if we had something at a single dose,” said Dr. Judith Feinberg, the vice chairwoman for research in medicine at West Virginia University, who was not involved in the study.
Only Phase 3 trials, which compare the effects of a vaccine with those of a placebo, can determine if a single dose is indeed effective, Dr. Feinberg said.
Another plus: The vaccine does not need to be frozen. The freezing requirement could make distribution difficult, especially to places without advanced medical facilities.
What’s next: The company’s chief scientific officer said Johnson & Johnson might be able to determine by the end of the year if the vaccine is safe and effective.
Article Courtesy of NY Times By Melina Delkic
LegendsTraveler ~ Keeping You Informed